Net Income: $255 million or $3.01 per share, compared to $254 million or $2.67 per share a year ago. Net Operating Income: $259 million or $3.07 per share, a 10% increase from a year ago. Return on Equity (GAAP): 19% through March 31. Book Value per Share (Excluding AOCI): $87.92, up 11% from a year ago. Life Insurance Premium Revenue: Increased 3% to $830 million. Life Underwriting Margin: $337 million, up 9% from a year ago. Health Insurance Premium Revenue: Grew 8% to $370 million. Health Underwriting Margin: Down 10% to $85 million. Administrative Expenses: $88 million for the quarter. American Income Life Premiums: Up 6% to $438 million. Liberty National Life Premiums: Grew 6% to $96 million. Family Heritage Health Premiums: Increased 9% to $112 million. Direct-to-Consumer Life Premiums: Down 1% to $246 million. United American Health Premiums: Increased 13% to $160 million. Excess Investment Income: $36 million, down approximately $8 million from a year ago. Net Investment Income: $281 million, down 1% from a year ago. Share Repurchases: Approximately 1.5 million shares for $177 million at an average price of $121.70 per share. RBC Ratio: 316% as of year-end 2024. Net Operating Earnings Guidance: Estimated range of $13.45 to $14.05 per diluted share for 2025. Warning! GuruFocus has detected 9 Warning Sign with GL. Release Date: May 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Globe Life Inc (NYSE:GL) reported a net operating income increase of 10% from the previous year, reaching $259 million or $3.07 per share. Life insurance premium revenue grew by 3% to $830 million, with a 9% increase in life underwriting margin driven by premium growth and lower policy obligations. The company expects life premium revenue to grow around 4% for the year, with life underwriting margins anticipated to be between 42% and 44%. Health insurance premium revenue increased by 8% to $370 million, despite a decrease in health underwriting margin due to higher claim costs. Globe Life Inc (NYSE:GL) repurchased approximately 1.5 million shares for $177 million, returning a total of $197 million to shareholders in the first quarter. Negative Points Health underwriting margin decreased by 10% to $85 million, primarily due to higher claim costs in United American resulting from increased utilization. Administrative expenses rose to $88 million, driven by higher information technology, employee, and legal costs. Net investment income decreased by 1% from the previous year, impacted by lower short-term interest rates. The direct-to-consumer division saw a 1% decline in life premiums and a 12% drop in net life sales due to reduced marketing spend and higher distribution costs. The company faces ongoing inquiries from the SEC and DOJ, with no material developments to disclose at this time. Story Continues Q & A Highlights Q: How soon will the health margin improvements from rate actions be reflected in results? A: Thomas Kalmbach, CFO, stated that almost all rate increases will be effective at the beginning of the second quarter, allowing the full benefit to be realized. Margins for United American General Agency (UAGA) are expected to be in the 5% to 7% range for the year. Q: What gives you confidence in achieving the EPS guidance range, especially with tough comps in the third quarter? A: Thomas Kalmbach, CFO, expressed confidence in the guidance range due to favorable mortality trends, which are expected to lead to positive remeasurement gains. Additionally, sales trends and agent count growth are in line with expectations, supporting the guidance. Q: How are you managing the increase in health claims usage and costs? A: Thomas Kalmbach, CFO, noted that while health claims usage has increased, the company is managing this through rate increases. It may take a year or two to fully catch up, but they have been successful in obtaining necessary rate approvals in the past. Q: Can you provide an update on the capital return strategy and share repurchase plans? A: Thomas Kalmbach, CFO, mentioned that share repurchases will continue to be the primary use of excess cash flows after dividends. The company plans to reduce commercial paper balances and maintain a debt-to-capital ratio around 25%. Q: What is the status of the regulatory inquiries by the SEC and DOJ? A: J. Matthew Darden, Co-CEO, stated there have been no material developments to disclose regarding the SEC and DOJ inquiries. The company will provide updates as more information becomes available. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
Globe Life Inc (GL) Q1 2025 Earnings Call Highlights: Strong Operating Income and Strategic ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...